Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

970
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
970

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nonspecific lower back pain in overhead athletes is multifactorial and is not solely determined by the type and intensity of the sport.

South African journal of sports medicine·2026
Same author

Muscle Membrane Permeability Determined by 31P-MRS and DT-MRI as a Biomarker for the Progression of Becker Muscular Dystrophy.

NMR in biomedicine·2026
Same author

Comments on Beyond Seizure Control: A Case Series on Levetiracetam Associated Psychiatric Manifestations.

Indian journal of psychological medicine·2026
Same author

Comments on: "The 30-Day Risk of Sudden Death in Patients With Epilepsy: A 10-Year Population-Based Cohort Study".

Journal of clinical neurology (Seoul, Korea)·2026
Same author

Diagnose Pediatric Delirium Preferentially by Psychiatric Examination, as CAPD Has Low Specificity.

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine·2026
Same author

In Reference to Bilateral Sudden or Chronic Hearing Loss as an Auditory Manifestation of Mitochondrial DNA Mutations.

The Laryngoscope·2025

Related Experiment Video

Updated: Jan 13, 2026

Analyzing Mitochondrial Transport and Morphology in Human Induced Pluripotent Stem Cell-Derived Neurons in Hereditary Spastic Paraplegia
07:32

Analyzing Mitochondrial Transport and Morphology in Human Induced Pluripotent Stem Cell-Derived Neurons in Hereditary Spastic Paraplegia

Published on: February 9, 2020

8.2K

Fampridine in Hereditary Spastic Paraplegia Type 4 With SPAST Variant c.683-2A>C: A Case Report.

Josef Finsterer1

  • 1Neurological Department, Neurology Neurophysiology Center, Vienna, Austria.

The American Journal of Case Reports
|January 7, 2026
PubMed
Summary

Fampridine may effectively treat hereditary spastic paraplegia type 4 (HSP4) caused by the SPAST c.683-2A>C variant. This case report suggests fampridine improves spasticity, gait, and walking speed in affected individuals.

More Related Videos

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

1.8K
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

34.6K

Related Experiment Videos

Last Updated: Jan 13, 2026

Analyzing Mitochondrial Transport and Morphology in Human Induced Pluripotent Stem Cell-Derived Neurons in Hereditary Spastic Paraplegia
07:32

Analyzing Mitochondrial Transport and Morphology in Human Induced Pluripotent Stem Cell-Derived Neurons in Hereditary Spastic Paraplegia

Published on: February 9, 2020

8.2K
Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

1.8K
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

34.6K

Area of Science:

  • Neurology
  • Genetics
  • Pharmacology

Background:

  • Hereditary spastic paraplegia (HSP) is primarily caused by mutations in the SPAST gene.
  • Current treatments for HSP are limited to symptom management.
  • Fampridine has shown efficacy in improving gait in some HSP patients, but its effect on HSP4 with the c.683-2A>C SPAST variant is unreported.

Purpose of the Study:

  • To report a case of HSP4 with the c.683-2A>C SPAST variant.
  • To evaluate the efficacy of fampridine as a symptomatic treatment for this specific HSP4 mutation.

Main Methods:

  • Clinical case report of a 63-year-old female with genetically confirmed HSP4 (c.683-2A>C SPAST variant).
  • Detailed description of patient's symptoms including gait disturbance, spasticity, and other neurological deficits.
  • Assessment of fampridine's effect on symptoms using standardized measures like the 6-meter walk test and Spastic Paraplegia Rating Scale.

Main Results:

  • The patient experienced significant relief from spasticity, gait disorders, and improved walking speed after initiating fampridine treatment.
  • Objective improvements were documented via the 6-meter walk test and Spastic Paraplegia Rating Scale.
  • The patient's sister, also affected by HSP4, exhibited a different progression rate and symptom severity.

Conclusions:

  • HSP4 associated with the c.683-2A>C SPAST variant can progress slowly and present with diverse phenotypes.
  • Fampridine demonstrates potential as a viable symptomatic treatment for HSP4, including cases with the c.683-2A>C mutation.
  • Further controlled studies are warranted to confirm fampridine's efficacy in a larger SPAST-HSP population.